Target Validation Information
TTD ID	T76914
Target Name	Voltage-gated potassium channel Kv1.3 (KCNA3)
Type of Target	Clinical trial
Drug Potency against Target	1-Benzyl-7-chloro-4-hexyloxy-quinolinium	Drug Info	IC50 = 828 nM	[6]
	2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide	Drug Info	IC50 = 150 nM	[2]
	4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	Drug Info	IC50 = 740 nM	[5]
	5-(4-Phenylbutoxy)psoralen	Drug Info	IC50 = 724 nM	[4]
	Correloid	Drug Info	IC50 = 184 nM	[3]
	CP-339818	Drug Info	IC50 = 230 nM	[1]
	UK-78282	Drug Info	IC50 = 280 nM	[1]
	[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine	Drug Info	IC50 = 1053 nM	[6]
References
REF 1	Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
REF 2	Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
REF 3	Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
REF 4	N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6983-8.
REF 5	Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
REF 6	Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.